Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Bcl-2/Bcl-XL Inhibitor LP-118

Review the clinical trials studying bcl-2/bcl-xl inhibitor lp-118 on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-2 of 2

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Status: Active
Location: 7 locations
LP-118 in Combination with Ponatinib, Vincristine and Dexamethasone for the Treatment of Relapsed or Refractory T Acute Lymphoblastic Leukemia and T Lymphoblastic Lymphoma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois